Effect of Soluplus^® on γ-cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation

References

• Abraham HMA, White CM, White WB. 2015. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 38(1):33–54.
   PubMed Web of Science ®Google Scholar
• Alopaeus JF, Hagesaether E, Tho I. 2019. Micellisation mechanism and behaviour of Soluplus®–furosemide micelles: preformulation studies of an oral nanocarrier-based system. Pharmaceuticals. 12(1):15.
   Web of Science ®Google Scholar
• Alshehri S, Imam SS, Altamimi MA, Hussain A, Shakeel F, Alshehri A. 2020. Stimulatory effects of Soluplus® on flufenamic acid β-cyclodextrin supramolecular complex: physicochemical characterization and pre-clinical anti-inflammatory assessment. AAPS PharmSciTech. 21(5):145.
   PubMed Web of Science ®Google Scholar
• Aly UF, Sarhan HA-M, Ali TFS, Sharkawy H-B. 2020. Applying different techniques to improve the bioavailability of candesartan cilexetil antihypertensive drug. Drug Des Devel Ther. 14:1851–1865.
   PubMed Web of Science ®Google Scholar
• Barreras A, Gurk-Turner C. 2003. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 16(1):123–126.
   PubMedGoogle Scholar
• Caron V, Hu Y, Tajber L, Erxleben A, Corrigan OI, McArdle P, Healy AM. 2013. Amorphous solid dispersions of sulfonamide/Soluplus® and sulfonamide/PVP prepared by ball milling. AAPS PharmSciTech. 14(1):464–474.
   PubMed Web of Science ®Google Scholar
• Chawla G, Bansal AK. 2007. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci. 32(1):45–57.
   PubMed Web of Science ®Google Scholar
• Fule R, Amin P. 2014. Development and evaluation of lafutidine solid dispersion via hot melt extrusion: investigating drug-polymer miscibility with advanced characterisation. Asian J. Pharm. Sci. 9(2):92–106.
   Google Scholar
• Higuchi T, Connors K. 1965. Phase-solubility techniques. Adv Anal Chem Instrum. 4(2):117–212.
   Google Scholar
• Hirlekar R, Kadam V. 2009. Preformulation study of the inclusion complex irbesartan-beta-cyclodextrin . AAPS PharmSciTech. 10(1):276–281.
   PubMed Web of Science ®Google Scholar
• Jansook P, Kulsirachote P, Loftsson T. 2018. Cyclodextrin solubilization of celecoxib: solid and solution state characterization. J Incl Phenom Macrocycl Chem. 90(1–2):75–88.
   Web of Science ®Google Scholar
• Jansook P, Pichayakorn W, Muankaew C, Loftsson T. 2016. Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B. Drug Dev Ind Pharm. 42(9):1446–1454.
   PubMed Web of Science ®Google Scholar
• Jansook P, Ritthidej G, Ueda H, Stefánsson E, Loftsson T. 2010. yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. J Pharm Pharm Sci. 13(3):336–350.
   PubMed Web of Science ®Google Scholar
• Koutsou GA, Storey DM, Bar A. 1999. Gastrointestinal tolerance of gamma-cyclodextrin in humans . Food Addit Contam. 16(7):313–317.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. 2012. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J Pharm Sci. 101(9):3019–3032.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Duchêne D. 2007. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 329(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Friðriksdóttir H. 1998. The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int J Pharm. 163(1–2):115–121.
   Google Scholar
• Loftsson T, Hreinsdóttir D, Másson M. 2005. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 302(1–2):18–28.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Hreinsdóttir D, Másson M. 2007. The complexation efficiency. J Incl Phenom Macrocycl Chem. 57(1–4):545–552.
   Web of Science ®Google Scholar
• Loftsson T, Másson M. 2004. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Deliv Sci Tech. 14(1):35–43.
   Web of Science ®Google Scholar
• Lorenzo-Soler L, Olafsdottir OB, Garhöfer G, Jansook P, Kristinsdottir IM, Tan A, Loftsson T, Stefansson E. 2021. Angiotensin receptor blockers in cyclodextrin nanoparticle eye drops: ocular pharmacokinetics and pharmacologic effect on intraocular pressure. Acta Ophthalmol. 99(4):376–382.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Veiga B, Sigurdsson HH, Loftsson T. 2019. Nepafenac-loaded cyclodextrin/polymer nanoaggregates: a new approach to eye drop formulation. Materials. 12(2):229.
   Web of Science ®Google Scholar
• Lorenzo-Veiga B, Sigurdsson HH, Loftsson T, Alvarez-Lorenzo C. 2019. Cyclodextrin-amphiphilic copolymer supramolecular assemblies for the ocular delivery of natamycin. Nanomaterials. 9(5):745.
   Web of Science ®Google Scholar
• Lourenco C, Teixeira M, Simões S, Gaspar R. 1996. Steric stabilization of nanoparticles: size and surface properties. Int J Pharm. 138(1):1–12.
   Google Scholar
• Muankaew C, Jansook P, Stefánsson E, Loftsson T. 2014. Effect of γ-cyclodextrin on solubilization and complexation of irbesartan: influence of pH and excipients. Int J Pharm. 474(1–2):80–90.
   PubMedGoogle Scholar
• Munro I, Newberne P, Young V, Bär A. 2004. Safety assessment of γ-cyclodextrin. Regul Toxicol Pharmacol. 39:3–13.
   PubMed Web of Science ®Google Scholar
• Mura P. 2014. Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: a review. J Pharm Biomed Anal. 101:238–250.
   PubMed Web of Science ®Google Scholar
• Mura P. 2015. Analytical techniques for characterization of cyclodextrin complexes in the solid state: a review. J Pharm Biomed Anal. 113:226–238.
   PubMed Web of Science ®Google Scholar
• Oparil S. 2000. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens. 13(1 Pt 2):18S–24S.
   PubMed Web of Science ®Google Scholar
• See S. 2001. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother. 2(11):1795–1804.
   PubMedGoogle Scholar
• Shi NQ, Zhang Y, Li Y, Lai HW, Xiao X, Feng B, Qi XR. 2017. Self-micellizing solid dispersions enhance the properties and therapeutic potential of fenofibrate: advantages, profiles and mechanisms. Int J Pharm. 528(1–2):563–577.
   PubMedGoogle Scholar
• Soe HMH, Chamni S, Mahalapbutr P, Kongtaworn N, Rungrotmongkol T, Jansook P. 2020. The investigation of binary and ternary sulfobutylether-β-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state. Carbohydr Res. 498:108190.
   PubMed Web of Science ®Google Scholar
• Sravya M, Deveswaran R, Bharath S, Basavaraj BV, Madhavan V. 2013. Development of orodispersible tablets of candesartan cilexetil-β-cyclodextrin complex. J Pharm. 2013:1–14.
   Google Scholar
• Tao C, Huo T, Zhang Q, Song H. 2019. Effect of Soluplus on the supersaturation and absorption of tacrolimus formulated as inclusion complex with dimethyl-β-cyclodextrin. Pharm Dev Tech. 24(9):1076–1082.
   PubMed Web of Science ®Google Scholar
• Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. 2012. Soluplus-solubilized citrated camptothecin-a potential drug delivery strategy in colon cancer. AAPS PharmSciTech. 13(1):59–66.
   PubMed Web of Science ®Google Scholar
• Thiry J, Krier F, Ratwatte S, Thomassin J-M, Jerome C, Evrard B. 2017. Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes. Eur J Pharm Sci. 96:590–597.
   PubMed Web of Science ®Google Scholar
• Thiry J, Lebrun P, Vinassa C, Adam M, Netchacovitch L, Ziemons E, Hubert P, Krier F, Evrard B. 2016. Continuous production of itraconazole-based solid dispersions by hot melt extrusion: preformulation, optimization and design space determination. Int J Pharm. 515(1–2):114–124.
   PubMedGoogle Scholar
• Van Haeringen NJ. 1996. The renin-angiotensin system in the human eye. Br J Ophthalmol. 80(2):99–100.
   PubMed Web of Science ®Google Scholar
• Vartak R, Patki M, Menon S, Jablonski J, Mediouni S, Fu Y, Valente ST, Billack B, Patel K. 2020. β-cyclodextrin polymer/Soluplus® encapsulated Ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV. Int J Pharm. 589:119863.
   PubMedGoogle Scholar
• Zhong Y, Jing G, Tian B, Huang H, Zhang Y, Gou J, Tang X, He H, Wang Y. 2016. Supersaturation induced by Itraconazole/Soluplus® micelles provided high GI absorption in vivo. Asian J Pharm Sci. 11(2):255–264.
   Web of Science ®Google Scholar